TO CONSULTING AGREEMENT Sample Clauses
TO CONSULTING AGREEMENT. This Amendment No. 4 to Consulting Agreement (“Amendment No. 4”) is made as of December 18, 2020, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One ▇▇▇▇▇▇▇ Square, Building 1400 West, Suite 14303, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“Company”) and ▇▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 (“Amendment”), dated as of November 4, 2002 and effective as of January 1, 2002 (the “Effective Date”) is entered into by and between Schrödinger, Inc. (“Schrödinger” or “Company”), a Delaware corporation with an address at ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇, and ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ (“Consultant”), an individual with an address at [**].
TO CONSULTING AGREEMENT. THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2023 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
TO CONSULTING AGREEMENT. Dear R▇▇▇▇▇▇: This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and R▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is entered into by and between AlloVir, Inc. (formerly ViraCyte, Inc.), a Delaware corporation (the “Company”), and ▇▇▇▇ ▇▇▇▇ (“Consultant”), effective generally as of January 1, 2020 (the “Effective Date”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of April 30, 2014 (“Effective Date”), by and between D▇▇▇▇▇▇▇ Advisors, LLC (“Consultant”), a corporation located at 9▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ and Vedantra Pharmaceuticals, Inc., a Delaware corporation (“Company”), located at One K▇▇▇▇▇▇ Square, Building 1▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇. Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between D▇▇▇▇▇▇▇ Advisors, LLC and the Company dated as of March 13, 2014 (“Agreement”).
TO CONSULTING AGREEMENT. Amendment No. 1 dated December 3, 1999 to the Consulting Agreement (the "Consulting Agreement") dated as of the 1st day of November, 1999 by Urban Cool Network, Inc. (the "Company") and RMH Consulting Corp. (the "Consultant").
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“First Modification”), executed this 8th day of February, 2012, is made by and between ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇. (“▇▇▇▇▇▇▇▇”), with an address of ▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, and Metro Bancorp, Inc. and Metro Bank (collectively, “Metro”), each with an office located at ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, Harrisburg, PA 17111.
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment No. 1”) is made as of September 19, 2022 (“Effective Date”), by and between bluebird bio, Inc., a Delaware corporation with a principal business address at ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“Company”) and ▇▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being ▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“▇▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between ▇▇▇▇▇▇▇▇ and the Company dated as of May 26, 2022 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (as defined below) (the “Amendment”) is entered into on December ___, 2007 by and among NovaRay, Inc., a Delaware corporation (the “Company”) and Fountainhead Capital Partners Limited (“Consultant”) (each a “Party” and collectively referred to hereafter as the “Parties”).